Why Jazz Pharmaceuticals (JAZZ) Stock Is Up Today

Jazz Pharmaceuticals (JAZZ) is up 3.8% today. Here is some analysis on what might have caused this price movement. ([investor.jazzpharma.com](https://investor.jazzpharma.com/news-releases/news-release-details/us-fda-approves-ziiherar-zanidatamab-hrii-and-without/?utm_source=openai))

Analysis: The most likely catalyst is the FDA approval announced on August 25, 2026 for Ziihera-based regimens in first-line HER2-positive advanced gastroesophageal adenocarcinoma. That decision expands Jazz’s commercial opportunity for zanidatamab and appears to have given investors confidence in a broader oncology growth runway. ([investor.jazzpharma.com](https://investor.jazzpharma.com/news-releases/news-release-details/us-fda-approves-ziiherar-zanidatamab-hrii-and-without/?utm_source=openai))

Details:

Jazz said the FDA approved Ziihera with and without tislelizumab plus chemotherapy for adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma in the first-line setting. ([investor.jazzpharma.com](https://investor.jazzpharma.com/news-releases/news-release-details/us-fda-approves-ziiherar-zanidatamab-hrii-and-without/?utm_source=openai))

The company had flagged August 25, 2026 as the PDUFA date earlier this year, so today’s action appears tied to that scheduled regulatory event being resolved positively. ([investor.jazzpharma.com](https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-announces-fda-acceptance-and-priority-0/?utm_source=openai))

Jazz had already told investors it was prepared to launch in this indication immediately following approval, which supports the view that the market is reacting to a near-term revenue opportunity rather than only a distant pipeline milestone. ([investor.jazzpharma.com](https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-announces-second-quarter-2026-financial?utm_source=openai))

The approval was supported by HERIZON-GEA-01 data published in May 2026, which showed median overall survival of 26.4 months for the zanidatamab, tislelizumab, and chemotherapy regimen versus 19.2 months for trastuzumab plus chemotherapy. ([investor.jazzpharma.com](https://investor.jazzpharma.com/news-releases/news-release-details/us-fda-approves-ziiherar-zanidatamab-hrii-and-without/?utm_source=openai))

Sources:

Jazz Pharmaceuticals, New England Journal of Medicine

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$JAZZ Insider Trading Activity

$JAZZ insiders have traded $JAZZ stock on the open market 31 times in the past 6 months. Of those trades, 0 have been purchases and 31 have been sales.

Here’s a breakdown of recent trading of $JAZZ stock by insiders over the last 6 months:

NEENA M PATIL (EVP & Chief Legal Officer) has made 0 purchases and 12 sales selling 56,792 shares for an estimated $10,932,950.
BRUCE C COZADD has made 0 purchases and 10 sales selling 36,000 shares for an estimated $7,853,023.
SAMANTHA PEARCE (EVP, Chief Commercial Officer) sold 6,907 shares for an estimated $1,625,976
MARY ELIZABETH HENDERSON (SVP, Technical Operations) sold 5,343 shares for an estimated $1,039,134
PATRICIA CARR (SVP, Chief Accounting Officer) has made 0 purchases and 3 sales selling 3,657 shares for an estimated $691,909.
RICK E WINNINGHAM sold 2,741 shares for an estimated $662,143
NORBERT G RIEDEL sold 3,415 shares for an estimated $655,680
HEATHER ANN MCSHARRY sold 2,000 shares for an estimated $482,000
MARK DOUGLAS SMITH sold 1,157 shares for an estimated $266,746

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$JAZZ Hedge Fund Activity

We have seen 364 institutional investors add shares of $JAZZ stock to their portfolio, and 303 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

FMR LLC added 2,333,564 shares (+102.5%) to their portfolio in Q2 2026, for an estimated $562,318,917
ECOR1 CAPITAL, LLC removed 1,706,469 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $411,207,834
JPMORGAN CHASE & CO added 1,160,786 shares (+inf%) to their portfolio in Q2 2026, for an estimated $279,714,602
NORGES BANK added 656,843 shares (+inf%) to their portfolio in Q2 2026, for an estimated $158,279,457
HOLOCENE ADVISORS, LP removed 572,914 shares (-78.1%) from their portfolio in Q2 2026, for an estimated $138,055,086
MARINER, LLC added 568,599 shares (+1420.9%) to their portfolio in Q2 2026, for an estimated $137,015,301
MILLENNIUM MANAGEMENT LLC removed 498,631 shares (-39.5%) from their portfolio in Q2 2026, for an estimated $120,155,112

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$JAZZ Price Targets

Multiple analysts have issued price targets for $JAZZ recently. We have seen 11 analysts offer price targets for $JAZZ in the last 6 months, with a median target of $265.0.

Here are some recent targets:

Gregg Gilbert from Deutsche Bank set a target price of $270.0 on 07/09/2026
Gregory Renza from Truist Securities set a target price of $254.0 on 07/07/2026
Jason Gerberry from B of A Securities set a target price of $307.0 on 06/10/2026
Etzer Darout from Barclays set a target price of $253.0 on 05/27/2026
Jeffrey Walch from Bernstein set a target price of $229.0 on 05/22/2026
David Amsellem from Piper Sandler set a target price of $301.0 on 05/22/2026
Ashwani Verma from UBS set a target price of $307.0 on 05/19/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.